Role of CD4 + and CD8 + T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome

Journal of Virology

Volumn 85, Issue 14, 2011, Pages 7256-7263

  Gheuens, Sarah ^a   Bord, Evelyn ^a   Kesari, Santosh ^b   Simpson, David M ^c   Gandhi, Rajesh T ^d   Clifford, David B ^e   Berger, Joseph R ^f   Ngo, Long ^a   Koralnik, Igor J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PEPTIDE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOGENESIS; IN VITRO STUDY; JC VIRUS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SURVIVOR; TREND STUDY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; INFLAMMATION; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

JC POLYOMAVIRUS;

EID: 79960418196     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02506-10     Document Type: Article

References (32)

1. Bonham, S., D. B. Meya, P. R. Bohjanen, and D. R. Boulware. 2008. Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med. 2:349-361.
2. Bourgarit, A., et al. 2006. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20:F1-F7.
3. Brickelmaier, M., et al. 2009. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother. 53:1840-1849.
4. Chen, Y., et al. 2009. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361:1067-1074.
5. Cianchetta-Sivori, M., S. Raso, M. Fernandez-Guerrero, M. Gorgolas, and R. Garcia. 2007. Do CD8(+)CD25(+) cells predict immune reconstitution syndrome in HIV-positive patients who begin HAART? AIDS 21:2347-2349.
6. Cinque, P., I. J. Koralnik, and D. B. Clifford. 2003. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J. Neurovirol. 9(Suppl. 1):88-92.
7. Cox, A. L., et al. 2005. Comprehensive analyses of CD8+ T-cell responses during longitudinal study of acute human hepatitis C. Hepatology 42:104-112.
8. Du Pasquier, R. A., et al. 2003. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1p36 in patients with proven or possible progressive multifocal leukoencephalopathy. J. Virol. 77:11918-11926.
9. Du Pasquier, R. A., et al. 2004. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127:1970-1978.
10. Elphick, G. F., et al. 2004. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380-1383.
11. Ford, E. S., C. E. Puronen, and I. Sereti. 2009. Immunopathogenesis of asymptomatic chronic HIV infection: the calm before the storm. Curr. Opin. HIV AIDS 4:206-214.
12. Gamadia, L. E., et al. 2003. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T-cells in protection against CMV disease. Blood 101:2686-2692.
13. Gasnault, J., et al. 2003. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17:1443-1449.
14. Gheuens, S., G. Pierone, P. Peeters, and I. J. Koralnik. 2010. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J. Neurol. Neurosurg. Psychiatry 81:247-254.
15. Goonetilleke, N., et al. 2006. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T-cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNAand modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80:4717-4728.
16. Johnson, T., and A. Nath. 2010. Neurological complications of immune reconstitution in HIV-infected populations. Ann. N. Y. Acad. Sci. 1184:106-120.
17. Khanna, N., et al. 2009. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J. Virol. 83:4404-4411.
18. Koralnik, I. J., et al. 2002. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J. Immunol. 168:499-504.
19. Letvin, N. L., et al. 2007. No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J. Virol. 81:12368-12374.
20. Lima, M. A., F. Bernal-Cano, D. B. Clifford, R. T. Gandhi, and I. J. Koralnik. 2010. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry 81:1288-1291.
21. + T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J. Virol. 81:3361-3368.
22. Linda, H., et al. 2009. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361:1081-1087.
23. Maher, S. G., A. L. Romero-Weaver, A. J. Scarzello, and A. M. Gamero. 2007. Interferon: cellular executioner or white knight? Curr. Med. Chem. 14:1279-1289.
24. Marzocchetti, A., et al. 2005. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J. Clin. Microbiol. 43:4175-4177.
25. Marzocchetti, A., et al. 2009. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73:1551-1558.
26. McCombe, J. A., et al. 2009. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 72:835-841.
27. Reusser, P., S. R. Riddell, J. D. Meyers, and P. D. Greenberg. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373-1380.
28. Tan, C. S., and I. J. Koralnik. 2010. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9:425-437.
29. Tan, K., R. Roda, L. Ostrow, J. McArthur, and A. Nath. 2009. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458-1464.
30. Urbani, S., et al. 2006. Outcome of acute hepatitis C is related to virusspecific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44:126-139.
31. Vendrely, A., et al. 2005. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 109:449-455.
32. Wenning, W., et al. 2009. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 361:1075-1080.